Osso VR has raised $27 million in a series B financing led by GSR Ventures. The funds will be used to accelerate expansion of its library and virtual reality (VR)-powered surgical training and assessment platform.
Tioga Medical Inc. closed a $30 million series B financing led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, Amed Ventures and Shifamed angel investors. The financing will be used to advance product development, support preclinical testing, and initiate clinical experience for the company's transcatheter mitral valve replacement technology.
Looking to allow customers to directly purchase its diagnostics system that runs a full panel of blood tests, Babson Diagnostics Inc. raised $31 million in new series B financing. The proceeds will be used to scale the Austin, Texas-based company to bring its finger-prick blood microsampling system to retail locations across the country.
It’s a good time to be a virtual research organization, with investors apparently eager to get into the segment. As part of that trend, Obviohealth Inc. reported it raised $31 million in series B financing, following on the heels of 4G Clinical's announcement on Tuesday of a $230 million investment by Goldman Sachs Asset Management and a $280 million transaction for Science 37 in May 2021.
Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue.
Cleerly Inc. snapped up $43 million in a series B fundraising round to develop artificial intelligence (AI)-enhanced imaging to better understand heart disease and more accurately project patient outcomes. Vensana Capital led the round with participation from the American College of Cardiology, Cigna Ventures, Dititx Partners, Lrvhealth (formerly Long River Ventures), New Leaf Venture Partners and returning investors.
Medtrace Pharma A/S raised $30 million in a series B round to ramp its platform for production, infusion and analysis of 15O-water in medical imaging. Swiss-based Swisscanto Invest, along with fund managers ATP and Bankinvest group from Denmark, are the lead investors. “We can now ramp our European and U.S. expansions plans in myocardial perfusion imaging and in other indications in need of perfusion data,” Martin Stenfeldt, CEO and co-founder of Medtrace, told BioWorld.
Synchron Inc. landed $40 million in new funding through a series B fundraising round led by Khosla Ventures. This round brings the total amount raised by the company to $59 million since its founding in 2016. Other participants in the round included Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, and Re.mind Capital as well as Arani Bose and Thomas Reardon. Returning investors included Neurotechnology Investors, Metis Innovative, and the University of Melbourne.
HONG KONG – Ultrasight Ltd. has closed a $13 million series B funding round, and is a step closer to entering the clinic in the U.S. with its cardiac ultrasound software. With the funds in hand, Rehovot, Israel-based Ultrasight aims to start clinical trials in the U.S. for its artificial intelligence (AI)-guided software for cardiac ultrasound.
PARIS – Microsure BV reported closing a $3.25 million funding round to develop its supermicrosurgery robot, Musa. This series B round was led by Dutch investment agency Invest-NL NV. The other 50% of the funding came from existing Dutch shareholders Brabant Development Agency NV and venture capital partners Innovation Industries Fund, as well as from Ten Cate Investreingsmaatschappij BV.